HMG 75IU Dosage Protocol

Educational guide for reconstitution and administration of HMG, a gonadotropin preparation studied for reproductive health and hormonal regulation.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (2 mL = 5 mg/mL)

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 10 mg vial provides only 2–4 days of research material at these doses.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Biological Action

HMG (Human Menopausal Gonadotropin) represents a highly purified extract from postmenopausal urine containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This gonadotropin preparation supports reproductive function through dual hormonal activity.

As a gonadotropin preparation, HMG binds to FSH and LH receptors to stimulate follicular development and ovulation. The FSH component promotes granulosa cell proliferation and estrogen production, while LH supports luteinization and progesterone synthesis.

HMG has been extensively studied in reproductive medicine for its role in supporting ovarian stimulation and maintaining hormonal balance during fertility treatments.

Potential Benefits & Side Effects

Findings from reproductive endocrinology and fertility research.

• Potential to support ovarian stimulation and follicular development in research settings
• May assist with hormonal regulation and reproductive function studies
• Associated with FSH and LH receptor activation and endocrine balance
• Generally well tolerated; occasional mild injection reactions or hormonal effects
• Long-term human safety data not established; this compound remains investigational

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References